Immunome: Regulatory filings and new study data - H.C. Wainwright sees 112% price potential!
Reading Time: 3 minutes
ESMO data demonstrate sustainable relief in aggressive desmoid tumors. Analysts see a price target of $40 as a signal for triple-digit price potential. PDUFA date in April 2027 will determine market introduction. Precision medicine in rare tumor diseases Immunome (IMNM) operates as a biopharmaceutical company focused on the development of targeted oncology and immunology therapies. The business model is based on the identification of novel antibodies through a proprietary B-cell hybridoma technology. The company addresses the structural...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
